GLP-1 Pills vs. Injections: Weight Loss Data

Do Oral GLP-1 Drugs Work as Well as Injectables? We Checked the Science

Do Oral GLP-1 Drugs Work as Well as Injectables? We Checked the Science
Adobe Stock; Novo Nordisk

For the millions of people using glucagon-like peptide-1 receptor agonists (GLP-1), a dose has long meant a weekly appointment with a needle. With the U.S. Food and Drug Administration (FDA) approving semaglutide (Wegovy) pills for weight management, a pill option is now available — with more approvals potentially to come.

Pills vs. Shots: The Weight Loss Data

Until recently, the stomach was a “dead zone” for GLP-1s because stomach acid and digestive enzymes break down peptides before the body can absorb all of them. New oral GLP-1s are designed to protect peptides, the active ingredients in these medications, so they can survive the trip through your digestive tract.

Based on clinical trials, the new semaglutide (Wegovy) pill has many of the same benefits as semaglutide that you inject into your body.

In the clinical trial that the FDA considered to approve Wegovy pills, adults taking 25 milligrams (mg) of the pills lost an average of 13.6 percent of their body weight over 64 weeks, compared with 2.2 percent in a placebo group.

In comparison, adults taking weekly injections of 2.4 mg of semaglutide lost an average of 14.9 percent of their body weight over 68 weeks, compared with 2.4 percent for the placebo group.

Why does it take a 25 mg daily pill to do the same job as a 2.4 mg weekly injection? The higher dose ensures enough of the drug survives the trip through your system to be effective. The actual effect of the medication is nearly the same.

“The absorption of the oral med from the [gastrointestinal] tract into the bloodstream is poor, such that the amount of medication entering the bloodstream is similar for the oral and injectable,”  says W. Timothy Garvey, MD, a professor of medicine at the University of Alabama at Birmingham.

Secondary Benefits

The benefits of these medications reach beyond the scale. Because the pill and the injection share the same active molecule, they deliver fairly similar improvements in blood sugar, and cholesterol.

Semaglutide Benefit
Injection (2.4 mg)
Pill (25 mg)
Blood Sugar (A1C)
-0.3%
-0.2%
Total Cholesterol
-3%
-2%

“The pill contains the same medicine as the injectable, and it’s highly likely that the health benefits will be the same,” Dr. Garvey says.

Like the semaglutide injection, the FDA approved the semaglutide pill for secondary prevention of major cardiovascular events such as heart attack and stroke in people with established cardiovascular disease who are overweight or who have obesity. But the FDA has not yet approved the semaglutide pill to treat the liver disease metabolic dysfunction-associated steatohepatitis (MASH), although it has approved the semaglutide injection for MASH. Early research suggests that the pill form of the GLP-1 may also improve liver fat and scarring, but no formal trials are complete.

And the benefits aren't just physical — they're mental, too. Because the pill mimics natural hormone functions, it travels to the brain to target the reward centers that drive overeating, says Sara Velayati, MD, an obesity medicine specialist at the Fleischer Institute Medical Weight Center at Montefiore Einstein in New York. This process helps quiet food noise, constant, intrusive thoughts about your next meal that can make weight management difficult.

Side Effects

Side effects of GLP-1 pills and injections for weight management are similar. Most people experience mild to moderate gastrointestinal (GI) issues, which usually fade as the body adjusts.

 Overall, 74 percent of people in trials for the 25 mg pills reported GI issues.

Semaglutide Side Effect
Injection (2.4 mg)
Pill (25 mg)
Nausea
44%
46.6%
Diarrhea
32%
17.6%
Vomiting
25%
30.9%
“Some patients taking weekly injectables do report more nausea on days two and three, but we will need more experience and data to see if patterns of nausea quantitatively differ between the oral and injectable,” Garvey says.

Administration

The biggest difference between GLP-1 shots and pills is your routine for taking the medication.

  • Injection You inject the medication under the skin once a week. You can take it with or without food, but you must keep the medicine refrigerated.

  • Pill You must take the pill daily, on an empty stomach, with 4 ounces of water or less. You must then wait at least 30 minutes before eating or drinking anything else, including other medications. If you don't wait, your body might not digest enough of the medicine.

“In my experience, waiting 30 minutes to eat does not present an undue burden on patients, who adjust to this just fine,” Garvey says.

Other GLP-1 Pills in the Pipeline

Although Wegovy is the first GLP-1 pill the FDA has approved for weight management, drug manufacturers are funding trials for additional oral GLP-1 medications.

  • orforglipron This small-molecule drug likely won't require the strict 30-minute fasting rule because the stomach does not break it down as easily. At its highest dose, 36 mg, participants in a phase 3 trial lost an average of 12.4 percent of their starting weight over 72 weeks.

     The manufacturer, Eli Lilly Co., has submitted orforglipron to the FDA for approval for use in weight management, with a decision expected in the second quarter of 2026.

  • aleniglipron Structure Therapeutics is testing this small-molecule oral GLP-1. Participants in its phase 2b trial lost an average of 14.2 percent of their body weight over 36 weeks using a daily 240 mg dose, the company says.

  • amycretin Novo Nordisk, which makes Wegovy and Ozempic, is testing this experimental, unimolecular drug to target two hormone pathways, GLP-1 and amylin, a hormone that helps control hunger. The mean weight loss among participants in its phase 1 trial was 13 percent of their starting body weight after 12 weeks.

The Takeaway

  • People who take oral GLP-1 medications for weight management have lost about the same amount of weight as those using injectable medications, according to research that the U.S. Food and Drug Administration used for approving the drugs.
  • Oral and injectable GLP-1s offer benefits beyond weight loss and may help you manage blood sugar, blood pressure, and cholesterol levels.
  • Side effects for GLP-1 pills and injectables are similar, mostly involving gastrointestinal issues, especially when you start taking medication for the first time.
  • The primary difference between the medication types is that you must take semaglutide pills daily, with food and beverage restrictions, while semaglutide injections are administered weekly.
  • Trials are underway for additional GLP-1 pills that may have fewer dietary restrictions.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. GLP-1 Agonists. Cleveland Clinic. July 3, 2023.
  2. Baral KC et al. Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. Pharmaceutics. March 21, 2025.
  3. Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England Journal of Medicine. September 17, 2025.
  4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. February 10, 2021.
  5. FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’. U.S. Food and Drug Administration. August 15, 2025.
  6. Zacharia GS et al. Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review. Cureus. October 28, 2025.
  7. Semaglutide Injection. Cleveland Clinic.
  8. Your Complete Guide to Wegovy Pill. Wegovy.
  9. Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England Journal of Medicine. September 16, 2025.
  10. Gardner J. Lilly, Chasing Novo, Expects Second-Quarter FDA Decision on Obesity Pill. Biopharma Dive. January 14, 2026.
  11. Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron. Structure Therapeutics. December 8, 2025.
  12. Gasiorek A et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the First-in-Class GLP-1 and Amylin Receptor Agonist, Amycretin: A First-in-Human, Phase 1, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet. July 12, 2025.

Adam Gilden, MD, MSCE

Medical Reviewer

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight Management and Wellness Clinic in Aurora. Dr. Gilden works in a multidisciplinary academic center with other physicians, nurse practitioners, registered dietitians, and a psychologist, and collaborates closely with bariatric surgeons.

Gilden is very involved in education in obesity medicine, lecturing in one of the obesity medicine board review courses and serving as the lead author on the Annals of Internal Medicine article "In the Clinic" on obesity.

He lives in Denver, where he enjoys spending time with family, and playing tennis.

Susan Jara

Author

Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging content for diverse audiences of patients and caregivers. She specializes in patient education, health literacy, and SEO-driven content strategy, with expertise across chronic disease, mental health, addiction, arthritis, autoimmune conditions, and wellness.

Susan holds a bachelor’s degree in journalism and media studies from New York University’s Gallatin School of Individualized Study. Her career includes leadership roles at the Global Healthy Living Foundation and Health Monitor Network, where she developed multichannel health content across web, email, podcasts, video, social media, and print. Susan's work reaches millions of readers each year, and she collaborates with leading healthcare providers, researchers, advocacy groups, and industry partners to create resources that reach millions of readers each year.